Factors Associated With Antipsychotic Polypharmacy and High-Dose Antipsychotics Among Individuals Receiving Compulsory Treatment in the Community

被引:10
|
作者
Gisev, Natasa [1 ]
Bell, J. Simon [2 ,3 ,4 ]
Chen, Timothy F. [1 ]
机构
[1] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia
[2] Monash Univ, Ctr Med Use & Safety, Fac Pharm & Pharmaceut Sci, Parkville, Vic, Australia
[3] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland
[4] Univ S Australia, Sansom Inst, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
关键词
antipsychotic agents; commitment of mentally ill; community mental health services; drug utilization; logistic models; LONG-ACTING INJECTIONS; TREATMENT ORDERS; SCHIZOPHRENIA; CLOZAPINE; DRUGS; AUGMENTATION; TOLERABILITY; PREVALENCE; KNOWLEDGE; ATTITUDES;
D O I
10.1097/JCP.0000000000000098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Community treatment orders (CTOs) are a form of compulsory treatment of individuals with a mental illness in the community. The objectives of this study were to determine the demographic, clinical, and treatment plan factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with a CTO. This was a secondary analysis of all 377 individuals who were prescribed an antipsychotic, extracted from a retrospective study of 378 individuals issued with a CTO by the New South Wales Mental Health Review Tribunal in Australia in 2009. Deidentified information relating to individuals' treatment plans, demographic, and clinical details were systematically extracted. Of the 377 individuals, 121 (32%) were prescribed antipsychotic polypharmacy and 101 (27%) high-dose antipsychotics. Unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for factors associated with antipsychotic polypharmacy and high-dose antipsychotics were computed using binary logistic regression. There was a strong association between the use of antipsychotic polypharmacy and high-dose antipsychotics (P < 0.001). Only treatment plan factors were associated with antipsychotic polypharmacy and high-dose antipsychotics in adjusted models. Although first-generation long-acting injectable antipsychotics and clozapine were associated with antipsychotic polypharmacy (adjusted OR, 9.12; 95% CI, 4.21-19.74; adjusted OR, 7.97; 95% CI, 2.93-21.72), oral second-generation antipsychotics and risperidone long-acting injection were associated with high-dose antipsychotics (adjusted OR, 5.67; 95% CI, 2.89-11.12; adjusted OR, 8.14; 95% CI, 3.22-20.53). Therefore, the use of antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with CTOs is associated only with the drugs prescribed in their treatment plans and not their individual demographic and clinical characteristics.
引用
收藏
页码:307 / 312
页数:6
相关论文
共 43 条
  • [1] Prescription patterns in psychiatric compulsory care: polypharmacy and high-dose antipsychotics
    Kaikoushi, Katerina
    Karanikola, Maria
    Middleton, Nicos
    Bella, Evanthia
    Chatzittofis, Andreas
    BJPSYCH OPEN, 2021, 7 (05):
  • [2] Antipsychotic Polypharmacy and High-Dose Antipsychotics in Involuntary Patients: a Seven-Year Audit of Discharge Prescriptions in an Acute Care Unit
    Martinho, Sergio
    Pocas, Ana
    Simoes, Mario
    Laureano, Claudio
    PSYCHIATRIC QUARTERLY, 2021, 92 (01) : 1 - 14
  • [3] Factors predicting high-dose and combined antipsychotic prescribing in New Zealand High-dose antipsychotic prescribing
    Burness, Celeste
    Corbet, Carla
    Beyene, Kebede
    Webby, Caitlin
    Nankivell, Charlotte
    Cabasag, Patrick
    Hari, Kinita
    Fraser, Allen
    Gray, Sarah
    Harrison, Jeff
    Chan, Amy Hai Yan
    PSYCHIATRY RESEARCH, 2021, 302
  • [4] Antipsychotic Polypharmacy Is Not Associated With Reduced Dose of Individual Antipsychotics in Schizophrenia
    John, Alexander Panickacheril
    Dragovic, Milan
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2015, 35 (02) : 193 - 195
  • [5] Antipsychotic polypharmacy and high-dose prescription in schizophrenia: a 5-year comparison
    Roh, Daeyoung
    Chang, Jhin-Goo
    Kim, Chan-Hyung
    Cho, Hyun-Sang
    An, Suk Kyoon
    Jung, Young-Chul
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2014, 48 (01) : 52 - 60
  • [6] Antipsychotic Polypharmacy and High-Dose Antipsychotic Regimens in the Residential Italian Forensic Psychiatric Population (REMS)
    Mandarelli, Gabriele
    Carabellese, Felice
    Di Sciascio, Guido
    Catanesi, Roberto
    FRONTIERS IN PSYCHOLOGY, 2022, 13
  • [7] Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia - a systematic review
    Lawrence, Christopher
    Roberts, Chloe
    Galides, Chloe
    Chamberlain, Samuel R.
    Hou, Ruihua
    JOURNAL OF PSYCHOPHARMACOLOGY, 2025, 39 (02) : 132 - 140
  • [8] Attitudes towards and rationale for antipsychotic polypharmacy among psychiatrists in Nigeria: Characteristics associated with high reported antipsychotic polypharmacy
    James, B. O.
    Omoaregba, J. O.
    Raji, S. O.
    Imishue, O. E.
    Okonoda, K. M.
    Nyamali, Y. I.
    Famuyiwa, P. A.
    Correll, C. U.
    PSYCHIATRY RESEARCH, 2017, 248 : 134 - 139
  • [9] Evaluation of the Individual Safe Correction of Antipsychotic Agent Polypharmacy in Japanese Patients with Chronic Schizophrenia: Validation of Safe Corrections for Antipsychotic Polypharmacy and the High-Dose Method
    Yamanouchi, Yoshio
    Sukegawa, Tsuruhei
    Inagaki, Ataru
    Inada, Toshiya
    Yoshio, Takashi
    Yoshimura, Reiji
    Iwata, Nakao
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2015, 18 (05) : 1 - 8
  • [10] Significance and Factors Associated with Antipsychotic Polypharmacy Utilization Among Publicly Insured US Adults
    Horvitz-Lennon, Marcela
    Volya, Rita
    Zelevinsky, Katya
    Shen, Mimi
    Donohue, Julie M.
    Mulcahy, Andrew
    Normand, Sharon-Lise T.
    ADMINISTRATION AND POLICY IN MENTAL HEALTH AND MENTAL HEALTH SERVICES RESEARCH, 2022, 49 (01) : 59 - 70